No Data
No Data
InflaRx | 6-K: Report of foreign private issuer (related to financial reporting)
Sector Update: Health Care Stocks Advance Monday Afternoon
Sector Update: Health Care
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
Express News | InflaRx Shares Are Trading Higher After the Company Announced GOHIBIC Was Selected by BARDA for a Phase 2 Study on Acute Respiratory Distress Syndrome
Express News | InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services